Aerobic bioprocesses rely heavily on the oxygen transfer rate (OTR) from sparged to dissolved gas. Given the low solubility of oxygen, the choice of mixer impeller configuration plays a crucial role in the design of a bioreactor vessel. This article delves into a series of experiments and computational fluid dynamics (CFD) simulations to elucidate how mixer configuration impacts the efficiency and effectiveness of a bioreactor vessel in terms of blend time and mass transfer.
The performance of aerobic bioprocesses hinges on the efficient transfer of oxygen, a process that is significantly influenced by the design of the agitator within the bioreactor vessel. Through a combination of experiments and computational fluid dynamics (CFD) simulations, the impact of different mixer configurations on blend time and mass transfer efficiency is explored in this article.
For further insights, readers can access the original article in Pharmaceutical Technology’s Biologics and Sterile Drug Manufacturing 2018 eBook, which offers a detailed exploration of the relationship between agitator design and bioreactor performance. When citing this article, please refer to it as authored by A. Strand and N. Courtemanche, titled “Impact of Agitator Design on Bioreactor Performance,” within the Pharmaceutical Technology Biologics and Sterile Drug Manufacturing eBook from May 2018.
The research presented in the article is led by Aaron Strand, PE, a senior research engineer at SPX FLOW (contact: aaron.strand@spxflow.com), and Nicolle Courtemanche, a senior application engineer at SPX FLOW (contact: nicolle.courtemanche@spxflow.com). Their work sheds light on the critical role of agitator design in enhancing bioreactor performance, emphasizing the significance of optimizing blend time and mass transfer efficiency.
To stay informed about the latest trends shaping the future of pharmaceutical manufacturing and compliance, consider subscribing to Pharmaceutical Technology for essential updates and breakthrough insights that can drive innovation in the industry.
In the realm of drug substance testing, advancements in therapeutic and analytical technologies are revolutionizing the process, enabling more efficient and accurate testing methodologies. By leveraging these advancements, pharmaceutical companies can enhance the quality and safety of their drug products while streamlining testing procedures for greater efficiency.
The Commissioner’s National Priority Vouchers Program offers a unique opportunity for stakeholders to share their perspectives and contribute to shaping the future of pharmaceutical research and development. By participating in such programs, industry players can influence policy decisions and drive innovation in areas of critical importance.
As the pharmaceutical landscape evolves, events like AAPS PharmSci 360 2025 play a pivotal role in showcasing the latest instrumentation innovations for bioanalysis. These advancements are instrumental in advancing drug development and analytical techniques, ultimately enhancing the quality and efficacy of pharmaceutical products.
The supply chain and distribution aspect of the life sciences industry is crucial in ensuring seamless delivery of drugs from the lab to the patient. By optimizing supply chain processes and leveraging efficient distribution strategies, pharmaceutical companies can enhance patient access to vital medications and improve overall healthcare outcomes.
Modern process control and automation technologies are bridging the gap in drug manufacturing by enabling precise and consistent production processes. By adopting these advanced technologies, pharmaceutical manufacturers can enhance product quality, increase efficiency, and ensure compliance with regulatory standards.
Transitioning from traditional trial-and-error approaches to rational design methodologies is key to driving efficiency in pharmaceutical formulation. By employing rational design strategies, researchers can expedite the drug development process, reduce costs, and enhance the overall quality of pharmaceutical formulations.
High-dose Nusinersen has significant implications for the care of patients with Spinal Muscular Atrophy (SMA), offering new treatment possibilities and therapeutic advancements. Understanding the impact of high-dose Nusinersen on SMA care is essential for healthcare providers to optimize treatment strategies and improve patient outcomes.
Located at 259 Prospect Plains Rd, Building H in Cranbury, NJ 08512, the pharmaceutical industry continues to drive innovation and advancements in drug development, manufacturing, and patient care. By staying at the forefront of technological and scientific progress, industry professionals can contribute to shaping the future of healthcare and pharmaceuticals.
Takeaways:
– The design of agitators in bioreactor vessels significantly impacts blend time and mass transfer efficiency, crucial for optimizing bioprocess performance.
– Advancements in therapeutic and analytical technologies are revolutionizing drug substance testing, enhancing quality and efficiency in pharmaceutical manufacturing.
– Participation in industry programs like the Commissioner’s National Priority Vouchers Program can influence policy decisions and drive innovation in pharmaceutical research and development.
Tags: bioreactor, formulation, automation
Read more on pharmtech.com